Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia

Bertalan Németh, Rita Bendes, Balázs Nagy, Árpád Götze, Kristóf Kóczián, Margit Horváth, Izabella Deák, Bernadett Tóth, Z. Kaló

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. Methods: To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public databases. Unit costs were based on tariffs of the National Health Insurance Fund Management. Key assumptions on treatment pathways and resource utilization were supported by experts to reflect clinical practice. These assumptions include the option of therapy switching, and selection of a 2-year time horizon. Deterministic and probabilistic sensitivity analyses were also conducted, together with scenario analyses. Results: The use of cariprazine resulted in 1.45 Quality-Adjusted Life Years (QALY) per patient, and a total cost of 3340 Euros per patient over a time horizon of 2 years. The use of risperidone resulted in 1.40 QALY/patient, and a total cost of 1896 Euros per patient. The incremental cost-effectiveness ratio (ICER) of the comparison between cariprazine and risperidone is therefore 28,897 Euros/QALY. The sensitivity analyses and the scenario analysis confirmed the robustness of the base-case results. Conclusions: Cariprazine compared to risperidone in the treatment of schizophrenia for patients with negative symptoms provides additional health gain at acceptable costs according to the willingness to pay threshold in Hungary. The findings of the analysis were proven to be robust in the scenario analyses and sensitivity analyses.

Original languageEnglish
JournalHealth Policy and Technology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Risperidone
Cost-Benefit Analysis
Schizophrenia
Cost effectiveness
Quality-Adjusted Life Years
Costs
Costs and Cost Analysis
Hungary
Health
Health insurance
Health Insurance Reimbursement
Literature
National Health Programs
Therapeutics
Antipsychotic Agents
cariprazine
Databases

Keywords

  • Cariprazine
  • Cost-utility analysis
  • Health economic modelling
  • Hungary
  • Schizophrenia

ASJC Scopus subject areas

  • Biomedical Engineering
  • Health Policy

Cite this

Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. / Németh, Bertalan; Bendes, Rita; Nagy, Balázs; Götze, Árpád; Kóczián, Kristóf; Horváth, Margit; Deák, Izabella; Tóth, Bernadett; Kaló, Z.

In: Health Policy and Technology, 01.01.2019.

Research output: Contribution to journalArticle

Németh, Bertalan ; Bendes, Rita ; Nagy, Balázs ; Götze, Árpád ; Kóczián, Kristóf ; Horváth, Margit ; Deák, Izabella ; Tóth, Bernadett ; Kaló, Z. / Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. In: Health Policy and Technology. 2019.
@article{f4868a0f608c42f3b44e2308ede3c9b4,
title = "Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia",
abstract = "Objectives: The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. Methods: To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public databases. Unit costs were based on tariffs of the National Health Insurance Fund Management. Key assumptions on treatment pathways and resource utilization were supported by experts to reflect clinical practice. These assumptions include the option of therapy switching, and selection of a 2-year time horizon. Deterministic and probabilistic sensitivity analyses were also conducted, together with scenario analyses. Results: The use of cariprazine resulted in 1.45 Quality-Adjusted Life Years (QALY) per patient, and a total cost of 3340 Euros per patient over a time horizon of 2 years. The use of risperidone resulted in 1.40 QALY/patient, and a total cost of 1896 Euros per patient. The incremental cost-effectiveness ratio (ICER) of the comparison between cariprazine and risperidone is therefore 28,897 Euros/QALY. The sensitivity analyses and the scenario analysis confirmed the robustness of the base-case results. Conclusions: Cariprazine compared to risperidone in the treatment of schizophrenia for patients with negative symptoms provides additional health gain at acceptable costs according to the willingness to pay threshold in Hungary. The findings of the analysis were proven to be robust in the scenario analyses and sensitivity analyses.",
keywords = "Cariprazine, Cost-utility analysis, Health economic modelling, Hungary, Schizophrenia",
author = "Bertalan N{\'e}meth and Rita Bendes and Bal{\'a}zs Nagy and {\'A}rp{\'a}d G{\"o}tze and Krist{\'o}f K{\'o}czi{\'a}n and Margit Horv{\'a}th and Izabella De{\'a}k and Bernadett T{\'o}th and Z. Kal{\'o}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.hlpt.2019.01.004",
language = "English",
journal = "Health Policy and Technology",
issn = "2211-8837",
publisher = "Fellowship of Postgraduate Medicine",

}

TY - JOUR

T1 - Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia

AU - Németh, Bertalan

AU - Bendes, Rita

AU - Nagy, Balázs

AU - Götze, Árpád

AU - Kóczián, Kristóf

AU - Horváth, Margit

AU - Deák, Izabella

AU - Tóth, Bernadett

AU - Kaló, Z.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. Methods: To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public databases. Unit costs were based on tariffs of the National Health Insurance Fund Management. Key assumptions on treatment pathways and resource utilization were supported by experts to reflect clinical practice. These assumptions include the option of therapy switching, and selection of a 2-year time horizon. Deterministic and probabilistic sensitivity analyses were also conducted, together with scenario analyses. Results: The use of cariprazine resulted in 1.45 Quality-Adjusted Life Years (QALY) per patient, and a total cost of 3340 Euros per patient over a time horizon of 2 years. The use of risperidone resulted in 1.40 QALY/patient, and a total cost of 1896 Euros per patient. The incremental cost-effectiveness ratio (ICER) of the comparison between cariprazine and risperidone is therefore 28,897 Euros/QALY. The sensitivity analyses and the scenario analysis confirmed the robustness of the base-case results. Conclusions: Cariprazine compared to risperidone in the treatment of schizophrenia for patients with negative symptoms provides additional health gain at acceptable costs according to the willingness to pay threshold in Hungary. The findings of the analysis were proven to be robust in the scenario analyses and sensitivity analyses.

AB - Objectives: The aim was to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary. Methods: To assess the cost-effectiveness of cariprazine, a deterministic 8-health state Markov cohort model was built. The analysis was performed from a third-party payer perspective. Data were gathered from relevant sources of the scientific literature and public databases. Unit costs were based on tariffs of the National Health Insurance Fund Management. Key assumptions on treatment pathways and resource utilization were supported by experts to reflect clinical practice. These assumptions include the option of therapy switching, and selection of a 2-year time horizon. Deterministic and probabilistic sensitivity analyses were also conducted, together with scenario analyses. Results: The use of cariprazine resulted in 1.45 Quality-Adjusted Life Years (QALY) per patient, and a total cost of 3340 Euros per patient over a time horizon of 2 years. The use of risperidone resulted in 1.40 QALY/patient, and a total cost of 1896 Euros per patient. The incremental cost-effectiveness ratio (ICER) of the comparison between cariprazine and risperidone is therefore 28,897 Euros/QALY. The sensitivity analyses and the scenario analysis confirmed the robustness of the base-case results. Conclusions: Cariprazine compared to risperidone in the treatment of schizophrenia for patients with negative symptoms provides additional health gain at acceptable costs according to the willingness to pay threshold in Hungary. The findings of the analysis were proven to be robust in the scenario analyses and sensitivity analyses.

KW - Cariprazine

KW - Cost-utility analysis

KW - Health economic modelling

KW - Hungary

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85061230179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061230179&partnerID=8YFLogxK

U2 - 10.1016/j.hlpt.2019.01.004

DO - 10.1016/j.hlpt.2019.01.004

M3 - Article

JO - Health Policy and Technology

JF - Health Policy and Technology

SN - 2211-8837

ER -